Kronik hepatit C tedavisinde pegile-interferon  ve ribavirin içeren rejimlerin etkinliği: Geriye  doğru bir bakış: Efficacy of regimens containing pegylated interferon and  ribavirin in the treatment of chronic hepatitis C: A retrospective  overview

Ayhan  Balkan; Orhan Batı; Taylan Metin; Murat Taner  Gülşen

doi:10.5152/EurJTher.2017.155

Authors

Ayhan Balkan Gaziantep Üniversitesi Tıp Fakültesi, Gastroenteroloji Anabilim Dalı
Orhan Batı Gaziantep Üniversitesi Tıp Fakültesi,İç Hastalıkları Anabilim Dalı
Taylan Metin Gaziantep Üniversitesi Tıp Fakültesi,İç Hastalıkları Anabilim Dalı
Murat Taner Gülşen Gaziantep Üniversitesi Tıp Fakültesi, Gastroenteroloji Anabilim Dalı

DOI:

https://doi.org/10.5152/EurJTher.2017.155

Keywords:

Pegile interferon alfa-2A + ribavirin, pegile interferon alfa-2B + ribavirin, hepatit C virüs ribo nükleik asit

Abstract

Amaç: Kronik hepatit C (KHC) hastalarında, interferonlu tedavilere cevabı, kalıcı viral yanıtı etkileyen faktörleri ve nüksü değerlendirmeyi amaçladık.
Yöntemler: Çalışmaya retrospektif olarak KHC’li 305 hasta alındı. Hastalara 48 hafta pegile interferon alfa-2A (PEG-IFN α-2A ) + ribavirin (RİB) veya pegile interferon alfa-2B (PEG-IFN α-2B) + RİB tedavisi verildi.
Bulgular: Tedavinin 48. haftasında, tedavi sonu virolojik yanıt (TSVY) 305 hastanın 151’inde (%49,5) saptandı. PEG-IFN α-2A + RİB kullanan hastaların 70’inde (%50,7), PEG-IFN α-2B + RİB kullanan hastaların 81’inde (%48,5) TSVY saptandı (p>0,05). Tedavi bitiminden 6 ay sonra, kalıcı virolojik yanıt (KVY) ise tüm hastaların 138’inde (%45,2) saptandı. PEG-IFN α-2A + RİB kullanan hastaların 63’inde (%45,7), PEG-IFN α-2B + RİB kullanan hastaların 75’inde (%45,9) KVY saptandı (p>0,05). Tedavi sonrası 35 (%11,6) hastada nüks görüldü.
Sonuç: KHC enfeksiyonunda verilen tedavi ile hastaların uzun dönem prognozları olumlu yönde etkilenmektedir. PEG-IFN α-2A + RİB ve PEG-IFN α-2B + RİB tedavisi ile hepatit C virüs ribo nükleik asit (HCV RNA) klirensinde henüz istenen düzeye ulaşılamamıştır. Bu nedenle yeni tedavi rejimlerine ihtiyaç duyulmaktadır.

Metrics

Metrics Loading ...

References

Chevaliez S. Virological tools to diagnose and monitor hepatitis C viruc infection. Clin Microbiol Infect 2011; 17: 116-21.

Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001; 34: 1000-5.

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.

Puoti M, Zanini B, Quinzan GP, Ravasio L, Paraninfo G, Santantonio T, et al. A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. J Hepatol 2004; 41: 312-8.

Moucari R, Ripault M-P, Martinot-Peignoux M, Voitot H, Cardoso AC, Stern C, et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009; 58: 1662-9.

Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52: 889-900.

Pearlman BL. Hepatitis C treatment update. Am J Med 2004; 117: 344-52.

Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon α-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.

Reddy KR, Wright TL, Pockros PJ, Schiffman M, Everson G, Reindollar R, et al. Efficacy and safety of Pegylated (40–kd) interferon alpha–2a compared with interferon alpha–2a in non–cirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-8.

Olut AI, Arı A, Ozgenc O, Avcı M, Caymaz SO. Genotip 1 ile infekte kronik hepatit C hastalarında Pegile interferon ve ribavirin tedavisinin etkinliği: duşuk ve yuksek viral yuk etkisinin karşılaştırılması. Ankem Derg 2011; 25: 164-8.

Gonçalves CB, Amaral KM, Sander GB, Martins NL, Pereira L, Picon PD. Effectiveness of alpha interferon (+ ribavirin) in the treatment of chronic viral hepatitis C genotypes 2 and 3 in a Brazilian sample. Arq Gastroenterol 2012; 49: 150-6.

Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138: 116-22.

Gheorghe L, Iacob S, Sporea I, Grigorescu M, Sirli R, Damian D, et al. Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting. J Gastrointestin Liver Dis 2007; 16: 23-9.

Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 370-81

Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493-9.

Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26: 122-7.

Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa- 2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.

Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.

Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 2002; 37: 500-6.

Xie Y, Xu DZ, Lu ZM, Luo KX, Jia JD, Wang YM, et al. Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi- center controlled trial. Hepatobiliar Pancreat Dis Int 2005; 4: 213-9.

Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 600-9.

Hadziyannis SJ, Sette Jr H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.

McHutchison JG, Poynard T, Esteban-Mur R, Davis GL, Goodman ZD, Harvey J, et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002; 35: 688-93.

Lee JE, Yoon NR, Kim JD, Song MJ, Kwon JH, Bae SH, et al. Durability of sustained virologic response in chronic hepatitis C: analof factors related to relapse after sustained virologic response with peginterferon plus ribavirin combination therapy. Korean J Gastroenterol 2011; 57: 173-9.

Reichard O, Glaumann H, Frydén A, Norkrans G, Wejstål R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999; 30: 783-7.

Khokhar N. Late relapse in chronic hepatitis C after sustained viral response to interferon and ribavirin. J Gastroenterol Hepatol 2004; 19: 471-2.

Heo J. Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response. Korean J Hepatol 2011; 17: 180-2.

Tahan V, Kalaycı C. Kronik Hepatit C Güncel Tedavisi. Tabak F, Balık İ, Tekeli E, (ed’ler). Viral hepatit 2007. Birinci baskı. Viral Hepatitle Savaşım Derneği Yayını, İstanbul 2006: 26.